Healthcare · Profile from Healthcare Research Companion
R1 RCM Inc. (formerly Accretive Health)
The largest US end-to-end revenue cycle outsourcing company for hospitals and health systems. It was founded in 2003 as Accretive Health and built on a single anchor client, Ascension, whose revenue cycle staff it took over in return for a base fee plus a share of the improvement. It went public in 2010, nearly collapsed after the 2012 Minnesota attorney general case over aggressive collection practices, was rescued in 2016 by TowerBrook and Ascension, renamed R1 RCM, rebuilt through acquisitions (Intermedix, SCI Solutions, VisitPay and, in 2022, the ~$4.1bn purchase of Cloudmed) and was taken private by TowerBrook and Clayton, Dubilier & Rice in a ~$8.9bn deal completed in November 2024. Since then it has bet heavily on AI and automation, with ~30,000 staff largely in India and the Philippines handling work that software is increasingly expected to do.
At a glance
- Founded
- 2003, Chicago, Illinois, as Accretive Health
- Founders
- Mary Tolan (former Accenture executive, CEO until 2013) and J. Michael Cline (founder of Accretive LLC, an investment firm)
- Headquarters
- Murray, Utah (434 W. Ascension Way), per SEC filings by 2024; Chicago-based through at least early 2019 (results releases datelined Chicago). No relocation announcement found, so the move date is unconfirmed. Large operations in India and the Philippines
- Ownership / structure
- NYSE listing 2010 (as AH); delisted 2014 during a restatement and later relisted, trading as R1 RCM on Nasdaq (RCM) (verify dates); taken private November 2024 by TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R)
- Leadership (2026)
- Joseph Flanagan, CEO (CEO from 2016; Lee Rivas was CEO in 2023–24 before Flanagan returned, reported, verify); Eric Tagliere, CIO (from June 2026, reported)
- Segment and buyer
- Revenue cycle management (RCM) services and technology. Buyers are hospitals and health systems (end-to-end outsourcing), physician groups and emergency medicine (via Intermedix), and providers buying modular services (Cloudmed revenue recovery, patient payments)
- Scale
- Revenue ~$2.25bn (2023) and ~$2.5bn+ (2024, approximate, verify); ~30,000 employees (approximate); Cloudmed serving thousands of hospitals (reported)
- Capital / price
- IPO at $12 (2010); TowerBrook–Ascension ~$200m preferred investment (2016); Cloudmed ~$4.1bn all-stock (2022); take-private at $14.30 per share, ~$8.9bn enterprise value (agreed August 2024, closed November 2024)
- Signature moves (incl. failures)
- Founding on Ascension (2003); IPO (2010); Minnesota AG lawsuit and near-collapse (2012); TowerBrook–Ascension rescue and rename (2016–17); physician and patient-payment roll-up (2018–21); Cloudmed (2022); take-private (2024); AI "revenue operating system" (2025)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2003
Founding Accretive Health and Ascension
Founding / anchor contract
2010
NYSE IPO
IPO
2012
Minnesota Attorney General Lawsuit
Regulatory settlement / crisis
2016
TowerBrook Ascension Recapitalization
Recapitalisation / restructuring
2018
Intermedix and Platform Acquisitions
Acquisitions (platform roll-up)
2022
Cloudmed Acquisition
Acquisition (all-stock)
2024
TowerBrook CDR Take Private
Take-private
2025
AI Revenue Operating System
AI launch / acquisition